REPORT HIGHLIGHTS


Click here to watch Part 2 of the Round Table Discussion 4 INVESTMENT IN NEW TECHNOLOGIES


There was a general perception from Pharma panelists that it is difficult for them to outsource the bioanalysis of new molecular constructs, or analyses involving novel workflows, particularly when investment in new analytical approaches and equipment is required. In addition, it was observed that some CROs prefer to invest in more headcount, rather than the implementation of routine sample handling automation. The discussion confirmed that this was often the reality and that CROs are traditional followers, rather than leaders when it comes to the implementation of novel approaches. They tend not to have spare resource to invest in the research required to be an early adopter of new technologies. It was observed that Pharma clients often want workflows to be performed in a certain way, while CROs find it easier to make capital investments if they can be used across a broad range of clients, so technology has to be flexible. However, some Pharma companies are open to their suggestion and preferred workflows being used by other clients of the CRO. It was considered that this can be particularly beneficial in the discovery environment, where it can help drive down costs.


Pharma often ask CROs to invest in the identical platform to that being used in the Pharma company’s own laboratories. In these cases, there is generally very little leeway for the CRO to suggest alternative approaches, or instrumentation that might attain the same endpoint. Different Pharmas often ask for different approaches, so the CRO needs to consider the cost benefits carefully. There was some openness by Pharma to consider alternative approaches to achieve the same goal.


www.bioanalysis-zone.com


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18